Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT-CY +/- Low-dose ATG for Lymphoid Malignancies in Allo-HSCT
NCT04118075Phase 2Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2019
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, antithymocyte globulin rabbit in lymphoid malignancy, sponsored by Shanghai Jiao Tong University School of Medicine. Started Jan 2019; status: completed.
02
Drugs
cyclophosphamideantithymocyte globulin rabbit
03
Conditions
lymphoid malignancy
Beyond the preview
Go deeper on NCT04118075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118075.